4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.000p
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: 1,250.00p
  • 52 Week Low: 590.00p
  • Currency: UK Pounds
  • Shares Issued: 15.54m
  • Volume: 0

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth
87.46% above the market average87.46% above the market average87.46% above the market average87.46% above the market average87.46% above the market average
50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average50.00% above the sector average

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio
93.91% above the market average93.91% above the market average93.91% above the market average93.91% above the market average93.91% above the market average
81.82% above the sector average81.82% above the sector average81.82% above the sector average81.82% above the sector average81.82% above the sector average
Price Book Ratio
80.5% below the market average80.5% below the market average80.5% below the market average80.5% below the market average80.5% below the market average
25.71% below the sector average25.71% below the sector average25.71% below the sector average25.71% below the sector average25.71% below the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
56.18% below the market average56.18% below the market average56.18% below the market average56.18% below the market average56.18% below the market average
31.82% below the sector average31.82% below the sector average31.82% below the sector average31.82% below the sector average31.82% below the sector average
Price Chg 3m
79.02% below the market average79.02% below the market average79.02% below the market average79.02% below the market average79.02% below the market average
63.64% below the sector average63.64% below the sector average63.64% below the sector average63.64% below the sector average63.64% below the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI
47.34% below the market average47.34% below the market average47.34% below the market average47.34% below the market average47.34% below the market average
46.34% below the sector average46.34% below the sector average46.34% below the sector average46.34% below the sector average46.34% below the sector average
Momentum 20
92.31% below the market average92.31% below the market average92.31% below the market average92.31% below the market average92.31% below the market average
90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin
94.53% below the market average94.53% below the market average94.53% below the market average94.53% below the market average94.53% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
54.43% below the market average54.43% below the market average54.43% below the market average54.43% below the market average54.43% below the market average
19.05% below the sector average19.05% below the sector average19.05% below the sector average19.05% below the sector average19.05% below the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover
82.1% below the market average82.1% below the market average82.1% below the market average82.1% below the market average82.1% below the market average
42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average
Operating Profit Loss
85.35% below the market average85.35% below the market average85.35% below the market average85.35% below the market average85.35% below the market average
61.9% below the sector average61.9% below the sector average61.9% below the sector average61.9% below the sector average61.9% below the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
9.13% above the market average9.13% above the market average9.13% above the market average9.13% above the market average9.13% above the market average
43.59% above the sector average43.59% above the sector average43.59% above the sector average43.59% above the sector average43.59% above the sector average
Cash
46.01% above the market average46.01% above the market average46.01% above the market average46.01% above the market average46.01% above the market average
65.85% above the sector average65.85% above the sector average65.85% above the sector average65.85% above the sector average65.85% above the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y
19.00% above the market average19.00% above the market average19.00% above the market average19.00% above the market average19.00% above the market average
9.09% above the sector average9.09% above the sector average9.09% above the sector average9.09% above the sector average9.09% above the sector average
Buys 1y
71.33% above the market average71.33% above the market average71.33% above the market average71.33% above the market average71.33% above the market average
48.39% above the sector average48.39% above the sector average48.39% above the sector average48.39% above the sector average48.39% above the sector average

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

4basebio Market Data

Currency UK Pounds
Share Price 590.00p
Closing Price Change 0.000p
% Change 0.00 %
52 Week High 1,250.00p
52 Week Low 590.00p
Volume 0
Shares Issued 15.54m

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
65.49% below the market average65.49% below the market average65.49% below the market average65.49% below the market average65.49% below the market average
12.20% above the sector average12.20% above the sector average12.20% above the sector average12.20% above the sector average12.20% above the sector average
Price Trend
34.27% below the market average34.27% below the market average34.27% below the market average34.27% below the market average34.27% below the market average
4.55% above the sector average4.55% above the sector average4.55% above the sector average4.55% above the sector average4.55% above the sector average
Income Not Available
Growth
59.11% above the market average59.11% above the market average59.11% above the market average59.11% above the market average59.11% above the market average
65.52% above the sector average65.52% above the sector average65.52% above the sector average65.52% above the sector average65.52% above the sector average

4basebio Dividends

No dividends found

Trades for --2026

Time Volume / Share Price
0 @ 0.000p

4basebio Key Personnel

CEO Heikki Lanckriet
CFO David John Roth

Top of Page